Unlearn, a developer specializing in digital replicas, recently disclosed its attainment of a series C funding round, securing an additional $50 million in investment. This funding, spearheaded by Altimeter Capital and supplemented by prior supporters including Insight Partners, 8VC, DCVC, and DCVC Bio, marks a milestone for the company. With this latest financial infusion, Unlearn has now amassed over $130 million in total fundraising throughout its operational history.
The allocation of these funds is intended to bolster various aspects of Unlearn’s operations, including expanding its workforce, enhancing computational capabilities, and advancing long-term research and development endeavors. CEO Charles Fisher, Ph.D, emphasized the company’s intention to broaden its therapeutic focus and amplify awareness of its innovative approach.
Unlearn’s technology revolves around leveraging artificial intelligence to scrutinize patient health records, fabricating digital replicas for each participant in clinical trials. These digital counterparts are then utilized to simulate potential outcomes if participants were administered a placebo treatment, thereby optimizing trial design and expediting drug development processes.
By integrating Unlearn’s predictive capabilities into clinical trials, researchers can streamline enrollment processes and minimize the reliance on traditional control groups. This not only maximizes the number of participants receiving experimental treatments but also accelerates the overall trial timeline. The company’s endeavors have garnered recognition from regulatory bodies, with qualifications from the European Medicines Agency and alignment with FDA guidelines for clinical trials in the United States.
In the domain of digital replica technology, Unlearn encounters competition from emerging entities like Twin Health. Unlike Unlearn’s trial-centric approach, Twin Health’s digital replica platform is positioned as a digital therapeutic tool. Leveraging AI algorithms, Twin Health’s Whole Body Digital Replica service analyzes user health data to generate personalized recommendations aimed at enhancing metabolic health.
Recent study outcomes published by Twin Health showcased promising results for individuals with Type 2 diabetes. Participants who received AI-powered interventions experienced substantial improvements, with average HbA1c levels decreasing from 9% to 6.1% over the course of a year. In contrast, the standard-of-care group exhibited marginal improvements, highlighting the potential of digital replica technology in driving positive health outcomes.
Despite the promising advancements in digital replica technology, Unlearn acknowledges persistent skepticism within the pharmaceutical industry regarding novel approaches. CEO Charles Fisher emphasizes the company’s commitment to dismantling these barriers and demonstrating the tangible value of digital replica technology in revolutionizing clinical research. He emphasized the company’s commitment to broadening its therapeutic focus and demonstrating the value of its digital twin technology in revolutionizing clinical research.
In a parallel development, Twin Health’s recent successful funding round further underscores the burgeoning interest and investment in digital replica solutions.
Unlearn’s recent achievement of securing $50 million in series C funding will be used by the company to expand its workforce, enhance computational capabilities, and advance long-term research projects.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
